Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNITY-ONE (NEJ029B): Nivolumab monotherapy in previously treated non-small-cell lung cancer
jRCTs031180013Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoint: Disease control rate at 9 weeks from nivolumab treatment. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180013.